Accessibility help Skip to navigation Skip to content Skip to footer

FT Health: Innovation in Healthcare

The final instalment of our series on innovation in European healthcare examines the effects of the slump in biotech valuations and changes in EU health policy

© Getty

Europe’s push to rival US biotech hubs faces hit from market slump
Rout revives fears of American buyers swooping on the continent’s start-ups
Streamlined EU process promises faster access to breakthrough drugs
‘Intricate dance’ under way to ensure simplified assessments of new medicines maintain quality and integrity
Pandemic bolsters EU’s role in health policy
‘There has been a change in attitudes. There are a lot of initiatives that were not foreseen a couple of years ago’
Finance, culture, talent: why Europe struggles to commercialise its biotech expertise
The continent is eager to capitalise on BioNTech’s Covid-19 success — but matching the scale of US hubs will be hard
EU pandemic strategy tries to bridge drug companies and civil society
Industry believes Covid response has shown innovation at its finest, but activists decry failure to provide equal access to vaccines
Data sharing holds key to progress on rare diseases in Europe
Inadequate infrastructure for international collaboration on research is the main obstacle to progress